Analyst Scoreboard: 5 Ratings For CytoSorbents
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for CytoSorbents (NASDAQ:CTSO) over the past quarter, with a majority being bullish. The average 12-month price target has increased to $8.2. CytoSorbents specializes in life-saving medical technologies and has shown revenue growth, though it faces challenges with debt management.
October 22, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CytoSorbents (NASDAQ:CTSO) has received mixed analyst ratings, with a majority being bullish. The average 12-month price target has increased to $8.2, indicating positive sentiment. However, the company faces challenges with high debt levels despite revenue growth.
The majority of analysts are bullish on CytoSorbents, with an increased average price target, suggesting positive short-term sentiment. However, the company's high debt-to-equity ratio could pose financial challenges, slightly tempering the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100